Researcher
Yana Dekempeneer
- Keywords:Medicine
Affiliations
- Medical Imaging (Research group)
Member
From1 Oct 2015 → Today - Supporting clinical sciences (Department)
Member
From15 Oct 2020 → Today - Supporting clinical sciences (Department)
Member
From1 Oct 2019 → 30 Jun 2020 - Supporting clinical sciences (Department)
Member
From8 Apr 2019 → 30 Sep 2019 - Faculty of Economic and Social Sciences and Solvay Business School (Faculty)
Member
From28 Sep 2016 → 13 Sep 2018 - Supporting clinical sciences (Department)
Member
From1 Oct 2015 → 20 Oct 2022 - Faculty of Medicine and Pharmacy (Faculty)
Member
From22 Sep 2015 → 2 Sep 2020
Publications
1 - 8 of 8
- Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment(2023)
Authors: T Ertveldt, Ahmet Krasniqi, Hannelore Ceuppens, Janik Puttemans, Yana Dekempeneer, Kevin De Jonghe, Wout De Mey, Q Lecocq, Y De Vlaeminck, R M Awad, et al.
Pages: 751-758 - Preclinical evaluation of 225Ac-labeled single-domain antibody for the treatment of HER2pos cancer(2022)
Authors: Magdalena Rodak, Yana Dekempeneer, Maria Wojewódzka, Vicky Caveliers, Peter Covens, Brian W Miller, Matthijs B Sevenois, Frank Bruchertseifer, Alfred Morgenstern, Tony Lahoutte, et al.
Pages: 1835-1845 - Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer.(2020)
Authors: Yana Dekempeneer, Vicky Caveliers, Maarten Ooms, Dominic Maertens, Mireille Gysemans, Tony Lahoutte, Catarina Xavier, Q Lecocq, Ken Maes, Peter Covens, et al.
Pages: 3553-3566 - Preclinical Targeted α- and β−-Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies(2020)
Authors: Janik Puttemans, Yana Dekempeneer, Jos Leon Eersels, Heleen Hanssens, P Debie, M Keyaerts, K Breckpot, Q Lecocq, Tony Lahoutte, Albert D Windhorst, et al.
- Targeted alpha therapy with single-domain antibody fragments, a novel cancer treatment(2020)
Authors: Yana Dekempeneer, Nick Devoogdt, Vicky Caveliers, Matthias D'Huyvetter
- Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior(2019)
Authors: Yana Dekempeneer, Tom Back, Emma Aneheim, Holger Jensen, Janik Puttemans, Catarina Xavier, M Keyaerts, Stig Palm, Per Albertsson, Tony Lahoutte, et al.
Pages: 3524-3533 - Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle(2016)
Authors: Yana Dekempeneer, M Keyaerts, Ahmet Krasniqi, Janik Puttemans, Serge Muyldermans, Tony Lahoutte, Matthias D'Huyvetter, Nick Devoogdt
Pages: 1035-47 - The Therapeutic Potential of Anti-HER2 2Rs15d Nanobody Labeled with 225Ac – an In Vitro and In Vivo EvaluationEdition: 1Volume: 50
Authors: Marek Pruszyński, Matthias D'Huyvetter, Magdalena Rodak, Yana Dekempeneer, Tony Lahoutte, Edyta Cedrowska, Frank Bruchertseifer, Alfred Morgenstern
Pages: S7-S7Number of pages: 1